CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-12 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Share Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-03-12 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Restricted Share Units | +50,000 | 50,000 | ||
| 2025-03-12 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Share Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-03-12 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Restricted Share Units | +15,000 | 15,000 | ||
| 2025-03-12 | DiFabio Andrea Chief Legal Officer | Grant or award · Share Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-03-12 | DiFabio Andrea Chief Legal Officer | Grant or award · Restricted Share Units | +15,000 | 15,000 | ||
| 2025-01-27 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +15,166 | $17.76 | $269K | 46,468 |
| 2025-01-27 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −15,166 | $40.46 | $614K | 31,302 |
| 2025-01-27 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +1,149 | $17.76 | $20K | 32,451 |
| 2025-01-27 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −1,149 | $41.07 | $47K | 31,302 |
| 2025-01-27 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,315 | 0 | ||
| 2025-01-24 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +22,468 | $17.76 | $399K | 53,770 |
| 2025-01-24 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −22,468 | $40.20 | $903K | 31,302 |
| 2025-01-24 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −22,468 | 16,315 | ||
| 2025-01-23 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +16,217 | $17.76 | $288K | 47,519 |
| 2025-01-23 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −16,217 | $40.08 | $650K | 31,302 |
| 2025-01-23 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,217 | 38,783 | ||
| 2024-12-18 | AULIN SHERRY Chief Financial Officer | Option exercise | +9,334 | $9.44 | $88K | 9,334 |
| 2024-12-18 | AULIN SHERRY Chief Financial Officer | Shares withheld for taxes | −2,135 | $41.28 | $88K | 7,199 |
| 2024-12-18 | AULIN SHERRY Chief Financial Officer | Sale | −7,199 | $41.23 | $297K | 0 |
Page 7 of 16 · 308 trades